OncoMatch/Clinical Trials/NCT04836507
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Is NCT04836507 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including CRC01 and Fludarabine for relapsed large b-cell lymphoma.
Treatment: CRC01 · Fludarabine · Cyclophosphamide — This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR philadelphia chromosome positive
Required: CD19 expression (≥ 90%)
Required: MYC double-hit
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: chemotherapy including rituximab and anthracycline (rituximab, anthracycline)
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: ineligible for or not consenting to asct
Cannot have received: anti-cd19/anti-cd3 therapy or any other anti-cd19 therapy
Cannot have received: adoptive t cell therapy
Cannot have received: gene therapy product
Cannot have received: allogeneic hsct
Cannot have received: oral anticoagulation therapy
Lab requirements
Blood counts
hemoglobin > 8.0g/dl; anc > 1,000/μl; alc ≥ 300/μl; platelets ≥ 50,000/μl
Kidney function
serum creatinine ≤ 1.5 x uln; egfr ≥ 60ml/min/1.73m2
Liver function
total bilirubin ≤ 2.0mg/dl (gilbert-meulengracht syndrome: ≤ 3 x uln and direct bilirubin ≤ 1.5 x uln); ast and alt ≤ 3 x uln (liver metastasis: ≤ 5 x uln)
Cardiac function
hemodynamically stable, without pericardial effusion and lvef ≥ 50% confirmed by echocardiogram (ecg) or multigated radionuclide angiography (muga)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04836507 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplantation, anti-cd19/anti-cd3 therapy or any other anti-cd19 therapy, adoptive t cell therapy disqualifies patients from enrollment.
Does this trial require BCR?
Yes, BCR philadelphia chromosome positive is a required biomarker for enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC double-hit is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify